Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOMP OUT: Ivonescimab in ACC or PPGL
NCT07743138Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2027
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab in adrenocortical carcinoma (ACC), pheochromocytoma and Paraganglioma (PGL) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate and Safety and adverse events at 1 year. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
adrenocortical carcinoma (ACC)pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT07743138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743138.